
Aravive ARAV
Quarterly report 2023-Q3
added 11-09-2023
Aravive Long Term Debt Current 2011-2026 | ARAV
Annual Long Term Debt Current Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 M | 2.3 M | 2.09 M | 2.39 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.39 M | 2.09 M | 2.24 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
3.58 M | $ 6.4 | - | $ 63.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 21.41 | - | $ 1 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
433 K | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 21.96 | - | $ 3.64 B | ||
|
Cardiff Oncology
CRDF
|
730 K | $ 1.72 | - | $ 115 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 1.91 | - | $ 397 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Galectin Therapeutics
GALT
|
22 K | $ 2.33 | - | $ 149 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 105.46 | - | $ 27.2 B | ||
|
Heron Therapeutics
HRTX
|
3.04 M | $ 1.19 | - | $ 198 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
ImmuCell Corporation
ICCC
|
85.5 K | $ 8.36 | - | $ 75.5 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.08 | - | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.26 | - | $ 2.96 B | ||
|
InflaRx N.V.
IFRX
|
257 K | $ 1.48 | - | $ 152 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.44 | - | $ 383 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Jaguar Health
JAGX
|
192 K | $ 0.39 | -0.18 % | $ 910 K | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 2.91 | - | $ 4.79 M | ||
|
KalVista Pharmaceuticals
KALV
|
1.62 M | $ 19.63 | - | $ 1.06 B | ||
|
Kamada Ltd.
KMDA
|
2.12 M | $ 8.28 | - | $ 260 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |